Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Tax Provisions (2022 - 2025)

Zentalis Pharmaceuticals has reported Tax Provisions over the past 4 years, most recently at $442000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $442000.0 for Q4 2025, up 315.61% from a year ago — trailing twelve months through Dec 2025 was $442000.0 (up 149.72% YoY), and the annual figure for FY2025 was $442000.0, up 149.72%.
  • Tax Provisions for Q4 2025 was $442000.0 at Zentalis Pharmaceuticals, up from -$205000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for ZNTL hit a ceiling of $442000.0 in Q4 2025 and a floor of -$605000.0 in Q2 2023.
  • Median Tax Provisions over the past 4 years was $17000.0 (2022), compared with a mean of -$34692.3.
  • Biggest five-year swings in Tax Provisions: tumbled 3658.82% in 2023 and later soared 315.61% in 2025.
  • Zentalis Pharmaceuticals' Tax Provisions stood at -$360000.0 in 2022, then soared by 62.5% to -$135000.0 in 2023, then tumbled by 51.85% to -$205000.0 in 2024, then soared by 315.61% to $442000.0 in 2025.
  • The last three reported values for Tax Provisions were $442000.0 (Q4 2025), -$205000.0 (Q4 2024), and -$27000.0 (Q3 2024) per Business Quant data.